🇺🇸 FDA

Drug profile · INN

paliperidone

BYANNLI (PREVIOUSLY PALIPERIDONE JANSSEN-CILAG INTERNATIONAL)

approved N05AX13
US status
approved
Patents linked
1
News articles
0

Quick answer

paliperidone (BYANNLI (PREVIOUSLY PALIPERIDONE JANSSEN-CILAG INTERNATIONAL)) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN paliperidone
Brand BYANNLI (PREVIOUSLY PALIPERIDONE JANSSEN-CILAG INTERNATIONAL)
Route ORAL
Formulation TABLET, EXTENDED RELEASE
ATC code N05AX13

Related patents

Search patents →

Frequently asked questions

What is paliperidone?

paliperidone (BYANNLI (PREVIOUSLY PALIPERIDONE JANSSEN-CILAG INTERNATIONAL)) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for paliperidone?

BYANNLI (PREVIOUSLY PALIPERIDONE JANSSEN-CILAG INTERNATIONAL) is a marketed brand name for paliperidone. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of paliperidone?

paliperidone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.